India's pharmaceutical industry needs to evolve from being primarily a cost-competitive manufacturing hub into a more innovation-driven global healthcare powerhouse, industry experts said.

India’s pharmaceutical industry needs to move beyond its traditional strength in low-cost generic medicines and accelerate investments in R&D, advanced manufacturing, biologics, digital technologies and CRDMO services to capture the next phase of global growth

India's pharmaceutical industry needs to evolve from being primarily a cost-competitive manufacturing hub into a more innovation-driven global healthcare powerhouse, industry experts said.

While the country has established a strong position in generic medicines, active pharmaceutical ingredients (APIs), vaccines and large-scale pharmaceutical manufacturing, experts believe the next phase of growth will require substantially higher investment in research and development, advanced technologies, quality systems and globally benchmarked manufacturing capabilities.

With India targeting a pharmaceutical market of around $130 billion by 2030, the industry is increasingly looking at higher-value segments such as biologics, biosimilars, cell and gene therapies, specialty medicines and contract research, development and manufacturing.

The discussions took place ahead of the 19th edition of CPHI & PMEC India 2026, scheduled to be held in November across venues in Delhi-NCR.

India’s Pharma Industry Enters a New Growth Phase

India has built a powerful pharmaceutical ecosystem based on its ability to manufacture high-quality medicines at competitive costs.

Indian pharmaceutical companies have become important suppliers to global markets, particularly in generic medicines and APIs. The country's large talent pool, manufacturing infrastructure and experience in highly regulated export markets have provided a strong foundation for continued expansion.

However, the global pharmaceutical industry is changing rapidly.

Drug discovery, biologics, precision medicine, digital technologies, artificial intelligence and advanced manufacturing are becoming increasingly important. As a result, industry leaders believe India needs to strengthen its capabilities beyond traditional generic-drug manufacturing.

The objective is not to abandon the country's cost advantage, but to combine that advantage with innovation and technology.

From Cost Competitiveness to Innovation

Industry experts said cost competitiveness will continue to remain an important strength for India, but it cannot be the only differentiator.

As pharmaceutical manufacturing expands across emerging markets, companies will increasingly compete on intellectual property, quality, speed, technology and innovation.

Chakravarthi AVPS, Chairman, Federation of Pharma Entrepreneurs, Telangana and Andhra Pradesh, said compliance has now become the baseline for pharmaceutical companies.

The next competitive advantage, according to industry leaders, will come from innovation, advanced and sustainable packaging, traceability, technology and globally benchmarked quality.

This represents a significant shift in the way India's pharmaceutical sector could approach growth over the coming decade.

R&D Investment to Become a Strategic Priority

Greater investment in research and development is expected to be one of the biggest requirements for India's pharmaceutical transformation.

Indian companies have historically focused heavily on generic medicines, where manufacturing efficiency and regulatory expertise are major advantages.

However, developing complex medicines and proprietary products requires substantially greater investment in scientific research.

Companies will need to build capabilities in drug discovery, clinical research, formulation development and advanced manufacturing.

Higher R&D spending could also help Indian pharmaceutical companies develop stronger intellectual-property portfolios and reduce dependence on products facing intense generic competition.

Biologics and Biosimilars Offer Major Opportunities

Biologics and biosimilars are emerging as important growth areas for the pharmaceutical industry.

These products require sophisticated research capabilities, specialised manufacturing infrastructure and advanced quality-control systems.

Pushpa Vijayaraghavan, Director, Healthcare and Lifesciences Advisory, Sathguru Management Consultants, said India needs to progress simultaneously across generics, APIs, biologics, biosimilars and innovation.

The opportunity in biologics could be particularly significant as global healthcare systems increasingly adopt advanced therapies.

Indian companies that successfully build capabilities in these areas could move towards higher-value segments of the global pharmaceutical market.

API Backward Integration Remains Important

India's pharmaceutical industry has significant capabilities in manufacturing APIs and bulk drugs, but dependence on imported key starting materials and intermediates remains a concern.

M Roja Rani, Executive Director, Bulk Drug Manufacturers Association of India, said India has established manufacturing capabilities but needs to strengthen the domestic value chain.

Reducing dependence on imported inputs could help pharmaceutical companies improve supply-chain resilience and reduce vulnerability to geopolitical disruptions, transportation bottlenecks and international price fluctuations.

Greater backward integration could also improve visibility over costs and raw-material availability.

Bulk Drug Parks Could Strengthen the Ecosystem

Government initiatives such as the Production Linked Incentive (PLI) scheme and bulk drug parks are expected to support the development of domestic pharmaceutical manufacturing.

Bulk drug parks can provide common infrastructure and reduce the cost of establishing manufacturing facilities.

The broader objective is to create a deeper domestic ecosystem for APIs and pharmaceutical intermediates.

Industry experts believe such initiatives could help India build greater self-reliance while maintaining its position as a competitive global supplier.

Telangana Targets Life Sciences Leadership

Telangana is seeking to move beyond its established position as a pharmaceutical manufacturing and vaccine hub.

Sarvesh Singh, CEO, Lifesciences and Pharma, Government of Telangana, said the state's ambition is to become India's life sciences innovation capital.

Telangana is increasingly focusing on areas where biotechnology, chemistry and technology intersect.

The state's strategy includes building capabilities in biologics, biosimilars, cell therapies, gene therapies and other next-generation life sciences segments.

Telangana’s $25 Billion Investment Target

Under its Next-Gen Life Sciences Policy 2026-2030, Telangana aims to attract approximately $25 billion in investments and create more than five lakh jobs over the next five years.

The target reflects the growing importance of life sciences in the state's industrial strategy.

If successfully implemented, the policy could encourage pharmaceutical companies, biotechnology firms, research organisations and global healthcare companies to expand their presence in the state.

The focus on innovation could also help Telangana compete for higher-value pharmaceutical investments rather than concentrating only on traditional manufacturing facilities.

CRDMO Sector Emerges as a Major Opportunity

The contract research, development and manufacturing organisation (CRDMO) industry is another area where India could see significant growth.

Global pharmaceutical companies increasingly outsource research, development and manufacturing activities to specialised partners.

India's scientific talent, manufacturing capabilities and cost advantage could make it an attractive destination for these activities.

Yogesh Mudras, Managing Director, Informa Markets in India, said the Indian CRDMO industry is projected to reach around $14 billion by 2028, with estimates suggesting an opportunity of up to $22 billion by 2030.

Why CRDMO Could Transform Indian Pharma

CRDMO businesses operate across multiple stages of the pharmaceutical development cycle.

Their services can include:

Drug discovery
Preclinical research
Clinical development
Process development
API development
Formulation development
Analytical testing
Contract manufacturing
Commercial-scale production

The expansion of this sector could help India capture a greater share of the global pharmaceutical value chain.

Instead of simply manufacturing finished generic medicines, Indian companies could increasingly participate in the research and development process itself.

Digital Technologies to Reshape Pharma

Digitalisation is expected to become another major driver of pharmaceutical-sector transformation.

Artificial intelligence, automation, data analytics and digital quality-management systems can improve manufacturing efficiency and supply-chain visibility.

AI can potentially assist pharmaceutical companies in areas such as drug discovery, molecule screening, clinical-trial analysis and manufacturing optimisation.

At the manufacturing level, automation and real-time data monitoring can improve consistency and reduce operational inefficiencies.

Traceability Becoming Essential

Global pharmaceutical markets are placing greater emphasis on product traceability.

Pharmaceutical companies need to demonstrate where products and ingredients originate and how they move through the supply chain.

Digital traceability systems can provide greater visibility across manufacturing and distribution networks.

This is particularly important in highly regulated markets, where quality failures can result in regulatory action, product recalls and reputational damage.

For Indian exporters, globally benchmarked quality and traceability could become increasingly important competitive advantages.

Advanced Manufacturing Could Improve Margins

The shift towards advanced manufacturing could also have financial implications for pharmaceutical companies.

Automation and modern production technologies can potentially improve productivity and reduce wastage.

Over time, higher utilisation and better manufacturing efficiency could support margins.

However, these benefits will depend on successful implementation and adequate utilisation of the additional capital invested in technology.

Sustainable Manufacturing Gains Importance

Sustainability is also becoming a greater priority across the global pharmaceutical supply chain.

International customers are increasingly looking at the environmental impact of manufacturing processes.

Pharmaceutical companies are therefore under pressure to improve energy efficiency, waste management, water usage and emissions.

Advanced and sustainable packaging could become another area of differentiation.

Companies that combine sustainability with operational efficiency could potentially improve their competitiveness in international markets.

India Must Protect Its Generic-Drug Strength

Despite the industry's push towards innovation, experts emphasised that India's generic-drug ecosystem remains an important competitive asset.

India has decades of experience in producing affordable medicines and supplying them to international markets.

The challenge is therefore not to replace generics with innovation but to build additional capabilities around the existing base.

The future pharmaceutical ecosystem could increasingly combine:

Generics + APIs + Biologics + Biosimilars + Specialty Medicines + CRDMO + Innovation.

Such diversification could make India's pharmaceutical industry more resilient and capable of capturing a larger share of global healthcare spending.

Global Regulatory Compliance Is Non-Negotiable

As Indian pharmaceutical companies move into more sophisticated markets, regulatory compliance will become even more important.

Global regulators maintain strict standards for manufacturing, product quality, clinical research and data integrity.

Compliance failures can lead to manufacturing restrictions, import alerts, product recalls and financial losses.

Industry experts therefore view compliance as the starting point rather than the final competitive advantage.

The companies that successfully combine compliance with innovation and speed could have a stronger position in global markets.

Global Partnerships Can Accelerate Growth

International partnerships could play an important role in India's pharmaceutical transformation.

Indian companies can gain access to advanced technologies, research capabilities and global distribution networks through strategic partnerships.

Collaborations with multinational pharmaceutical companies, biotechnology firms, research institutions and technology providers could accelerate the development of complex products.

Such partnerships may also help Indian companies enter higher-value global markets.

Supply-Chain Resilience Remains Critical

The pharmaceutical industry has become increasingly focused on supply-chain resilience following disruptions caused by geopolitical tensions, logistics problems and raw-material shortages.

Reducing dependence on a limited number of international suppliers could help Indian manufacturers improve reliability.

Domestic API production and greater backward integration could therefore become strategic priorities.

At the same time, companies may continue to diversify international suppliers to avoid excessive dependence on any single geography.

Talent Will Determine the Next Phase

Innovation-led growth will require a specialised workforce.

India already has a large pool of pharmaceutical professionals, engineers and scientists, but the next generation of growth will require deeper expertise in emerging technologies.

Areas likely to see rising demand include:

Biotechnology
Drug discovery
Clinical research
Artificial intelligence
Data science
Biologics
Gene therapy
Cell therapy
Advanced manufacturing
Regulatory science

Investment in talent development could therefore become as important as investment in physical infrastructure.

Government Support Could Accelerate Transformation

Government policy will remain an important catalyst for the pharmaceutical sector.

PLI schemes, bulk drug parks and state-level life sciences policies can encourage investment in manufacturing and research.

However, policy support alone cannot create sustainable innovation.

Private-sector companies will need to invest in R&D, technology, skilled employees and global-quality infrastructure.

The ability to convert government incentives into commercially viable businesses will determine the long-term success of these initiatives.

CPHI & PMEC India 2026 to Focus on Industry Opportunities

The industry discussions were held ahead of the 19th edition of CPHI & PMEC India 2026.

CPHI India will be held at IICC, Yashobhoomi, Dwarka, from November 23 to 25, while PMEC India will take place at IEML, Greater Noida, from November 24 to 26.

The event is expected to bring together pharmaceutical manufacturers, technology providers, research organisations, investors and other stakeholders from the life sciences ecosystem.

The discussions are likely to focus on innovation, manufacturing technologies, global partnerships and the future growth opportunities available to India's pharmaceutical industry.

India's $130 Billion Pharma Opportunity

India's target of reaching a pharmaceutical market size of around $130 billion by 2030 represents a significant opportunity.

However, achieving this target will require more than simply expanding generic-drug production.

The industry will need to increase its presence across the entire pharmaceutical value chain.

That includes research and development, APIs, biologics, biosimilars, specialty medicines, clinical research, CRDMO services and advanced manufacturing.

Key Growth Opportunities

The pharmaceutical sector could benefit from several structural growth drivers over the coming years:

Rising global demand for affordable medicines
Expansion of India's domestic healthcare market
Growth in biologics and biosimilars
Increasing pharmaceutical outsourcing
Expansion of the CRDMO industry
API backward integration
Government manufacturing incentives
Greater adoption of digital technologies
Growth in specialty medicines
Increasing global partnerships
Advanced and sustainable manufacturing

Companies with exposure to multiple growth areas could be better positioned to benefit from the sector's structural transformation.

Key Risks for Investors

The shift towards innovation also comes with significant risks.

R&D-heavy businesses may require large investments before generating meaningful revenues.

Drug-development timelines can be long, while clinical and regulatory outcomes remain uncertain.

Pharmaceutical companies also face pricing pressure, regulatory scrutiny, intellectual-property risks and intense global competition.

Investors should therefore distinguish between companies that are simply increasing R&D spending and those that are successfully converting research investments into commercially viable products.

What Investors Should Track

Investors evaluating pharmaceutical companies should monitor several operational and financial indicators.

These include:

R&D expenditure as a percentage of revenue
New product launches
Product pipeline
Regulatory approvals
Biologics and biosimilar development
API backward integration
CRDMO order book
Export growth
Manufacturing utilisation
EBITDA margins
Return on capital employed
Free cash flow
Debt levels
Regulatory observations
Intellectual-property portfolio

A combination of strong financial performance and sustainable innovation could become increasingly important for pharmaceutical valuations.

Market Outlook

India's pharmaceutical industry is moving towards a new growth model in which cost competitiveness remains a foundation, but innovation, technology and quality are becoming the primary differentiators. The country's established strengths in generics, APIs, vaccines and manufacturing provide a strong base, but the larger opportunity lies in capturing a greater share of the global value chain.

The projected expansion of India's CRDMO industry to around $14 billion by 2028 and potentially $22 billion by 2030 highlights the scale of the opportunity in contract research, development and manufacturing. Biologics, biosimilars, specialty medicines, advanced therapies and digital pharmaceutical technologies could create additional avenues for growth.

Government initiatives such as the PLI scheme, bulk drug parks and Telangana's Next-Gen Life Sciences Policy could support investment, but private-sector execution will remain critical.

For investors, the most important shift will be from volume-led pharmaceutical growth towards value-led growth. Companies with strong R&D capabilities, differentiated products, API integration, CRDMO exposure, advanced manufacturing, robust regulatory compliance and healthy cash flows could be better positioned for the next phase of the sector's expansion. However, investors should also watch R&D intensity, execution risks, regulatory developments, debt levels and the ability of companies to commercialise their innovation. India's $130 billion pharmaceutical ambition is therefore not simply a target for market expansion—it represents a broader transformation from India being primarily a cost-efficient global medicine supplier to becoming a technology-, research- and innovation-driven pharmaceutical and life sciences hub.